Skip to main content
OpenTrials
Completed

NCT Number: NCT01765972

Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear

The primary purpose of this clinical trial is to evaluate the eye's response to three test soft contact lenses as well as no lens wear, with respect to Corneal Staining.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Waterloo, Ontario, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  • The subject must be between 18 and 45 years of age.
  • The subject must be an adapted soft contact lens wearer in both eyes.
  • The subject must be of East or Southeast Asian descent, e.g. ethnic Chinese, Japanese, Korean, Malay, Vietnamese, Indonesian, Filipino, etc. (it is preferred but not required that both the subject's biological parents are East or Southeast Asian ethnicity, by self report).
  • The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D in each eye.
  • The subject's refractive cylinder must be no more than 1.00D in each eye.
  • The subject must have best corrected visual acuity of +0.14 logMAR (equivalent to 20/25-2) or better in each eye.
  • Subjects must own a wearable pair of spectacles and wear them on the day of the initial visit, during the washout before each phase and during the no lens wear phase.
  • The subject must have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion criteria

  • Are currently pregnant or lactating by self report (subjects who become pregnant during the study will be discontinued).
  • Have any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but may not be limited to, diabetes. hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes, HIV/AIDS, hepatitis, and tuberculosis.
  • Use of any topical medications such aas eye drops or ointments.
  • Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosion, or aphakia.
  • Had any previous, or planned ocular or intraocular surgery (e.g. cataract surgery, radial keratotomy, PRK, LASIK, etc.).
  • Have any grade 2.0 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale or any other ocular abnormality that may contraindicate contact lens wear.
  • Have any known hypersensitivity or allergic reaction to one of the study products.
  • Have any ocular infection.
  • Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  • Have any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV by self report).
  • Currently wear their contact lenses on an extended wear basis.
  • Are an employee of the investigational clinic (e.g. Investigator, Coordinator, Technician)

Treatment and study plan

etafilcon A with Lacreon

Device

contact lens with Lacreon

Other names: Test 1

etafilcon A with Lacreon with print

Device

contact lens with Lacreon and cosmetic print

Other names: Test 2

etafilcon A with print

Device

contact lens with print

Other names: Test 3

Spectacles (habitual)

Device

Spectacles

Primary outcomes

  1. Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit

    Time frame: 8 hours post fit

    Central corneal thickness was measured at baseline and 8-hour post fit with a modified optical pachometer on a Zeiss biomicroscope, interfaced to a PC. The pachometry measurement included seven readings; the computer is programmed to remove the high and low readings and to calculate the average of the remaining five readings. Only a single central corneal thickness measurement, the average of the 5 readings, was recorded by the investigator in the eCRF. The average percent change from baseline of corneal swelling was reported and was calculated as: ((Post fit - Baseline)/ Baseline) X 100.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Vision Care, Inc.

Industry

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Jan 11, 2013
Registry last updated
Jun 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.